CRISPR/Cas9 BCL11A Enhancer Targeting for Fetal Hemoglobin
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for β-hemoglobinopathies, such as sickle cell anemia and β-thalassemias, are limited by the inability to effectively reactivate fetal hemoglobin production in adults, which could ameliorate disease severity, due to the lack of understanding of the molecular mechanisms governing the globin switch.
Innovation Solution
Targeting specific functional regions within the BCL11A enhancer region using CRISPR/Cas9 technology to disrupt BCL11A expression, thereby increasing fetal hemoglobin levels by designing small guide RNA sequences to cleave genomic DNA at defined sites on chromosome 2, specifically at the +62, +58, and +55 functional regions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CRISPR/Cas9 technology is used to target BCL11A enhancer regions, then fetal hemoglobin production is reactivated, but the complexity of the treatment increases
Solution Approach 1:
The patent segments the BCL11A enhancer region into three distinct functional regions (+62, +58, and +55) that can be independently targeted by specific guide RNAs. This segmentation allows for precise, modular targeting of the enhancer region, enabling researchers to selectively disrupt specific functional elements while leaving others intact, thus managing treatment complexity through systematic division of the target site.
Solution Approach 2:
The patent uses guide RNAs as intermediaries that mediate between the CRISPR/Cas9 system and the BCL11A enhancer regions. These guide RNAs serve as specific molecular mediators that direct the Cas9 enzyme to precise locations within the enhancer, enabling targeted disruption without requiring direct manipulation of the entire enhancer region, thereby simplifying the overall approach.
2Manufacturing precision
If specific functional regions of BCL11A enhancer are targeted, then manufacturing precision of genetic modification is improved, but the difficulty of detecting and measuring target sites increases
Solution Approach 1:
The patent performs preliminary identification and characterization of the BCL11A enhancer functional regions before attempting genetic modification. By pre-mapping the enhancer regions and identifying their specific functional elements (+62, +58, +55), the patent establishes clear target coordinates for CRISPR/Cas9 targeting, thereby facilitating precise genetic modification while reducing the difficulty of subsequent detection and measurement through advance preparation of target site information.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach leads to enhanced fetal hemoglobin enrichment, providing a therapeutic strategy to interfere with adult hemoglobin production and induce fetal hemoglobin synthesis, potentially alleviating the severity of β-hemoglobinopathies.
Implementation Method 1
targeting specific functional regions within the BCL11A enhancer region using CRISPR/Cas9 technology to disrupt BCL11A expression, thereby increasing fetal hemoglobin levels by designing small guide RNA sequences to cleave genomic DNA at defined sites on chromosome 2
Implementation Method 2
contacting the cell with an effective amount of a composition comprising a nucleic acid molecule described herein or a vector comprising the nucleic acid molecule described herein, together with at least a DNA-targeting endonuclease whereby the DNA-targeting endonuclease cleaves the genomic DNA of the cell
Data Source
Figure 1A~1E
Figure 2A~2E
Figure 2F~2H
AI summary
Provided herein are nucleic acid molecules that target the BCL11A enhancer functional regions, compositions comprising the nucleic acid molecules and methods for increasing fetal hemoglobin levels in a cell by disrupting BCL11A expression at the genomic level. Also provided herein are methods and compositions relating to the treatment of hemoglobinopathies by reinduction of fetal hemoglobin levels. In particular, the nucleic acid molecules target the +62, +58, and/or the +55 enhancer functional regions.